Date of preparation March 2016 INT-ABR160015
Designing a continuum of care in MPC
2
nd
-line MM-398 + 5-FU/LV provides a break from neurotoxicity, paving the way for subsequent 3
rd
-line
treatment
Prior exposure to irinotecan (with 1
st
-line FOLFIRINOX) could increase the potential for resistance to 2
nd
-
line MM-398
1
st
line
2
nd
line
3
rd
line
Nab-paclitaxel +
gemcitabine
8.7 m
MM-398+
5-FU/LV
6.1 m
FOLFOX/OFF
Oettle & Lehmann, Lancet 2016;387:507-8
